TRIM28 and neoplasm: Notably, TRIM28 knockdown has been associated with increased responsiveness to anti‐PD‐1 therapy in immunocompetent mice, evidenced by higher levels of CD8+ T tumor‐infiltrating lymphocytes and decreased numbers of myeloid‐derived suppressor cells.277